11:34 AM EST, 11/04/2025 (MT Newswires) -- Royalty Pharma ( RPRX ) said Tuesday it has acquired a royalty interest in Alnylam Pharmaceuticals' ( ALNY ) Amvuttra from Blackstone (BX) Life Sciences-managed funds for $310 million.

Royalty Pharma ( RPRX ) said it acquired Blackstone's 1% royalty on global net sales of Amvuttra, a treatment of a disease caused by misfolded proteins that pile up in the nerves, heart and GI tract.

The transaction is for Amvuttra sales starting on Oct. 1, with the royalty duration extending through March 2035, Royalty Pharma ( RPRX ) said.

The deal excludes fixed payments paid to Blackstone as part of the original transaction, when Blackstone invested $70 million.

Price: 37.95, Change: +0.65, Percent Change: +1.74